CAMP · Categories · Coverage

CAMP - Analyst coverage initiated

CAMP4 Therapeutics Corporation (CAMP) analyst coverage initiated - real-time wire coverage filtered to Coverage only.

Recent Coverage for CAMP

• 12d
  Raymond James initiated coverage on CAMP4 Therapeutics with a new price target

  Raymond James initiated coverage of CAMP4 Therapeutics with a rating of Strong Buy and set a new price target of $10.00
• 20d
  Needham initiated coverage on CAMP4 Therapeutics with a new price target

  Needham initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $8.00
• 30d
  Oppenheimer initiated coverage on CAMP4 Therapeutics with a new price target

  Oppenheimer initiated coverage of CAMP4 Therapeutics with a rating of Outperform and set a new price target of $15.00
• 147d
  Chardan Capital Markets initiated coverage on CAMP4 Therapeutics with a new price target

  Chardan Capital Markets initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $6.50
• 204d
  Rodman & Renshaw initiated coverage on CAMP4 Therapeutics with a new price target

  Rodman & Renshaw initiated coverage of CAMP4 Therapeutics with a rating of Buy and set a new price target of $7.00
• 398d
  Cantor Fitzgerald initiated coverage on CAMP4 Therapeutics with a new price target

  Cantor Fitzgerald initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $7.00
• 526d
  Wedbush initiated coverage on CAMP4 Therapeutics with a new price target

  Wedbush initiated coverage of CAMP4 Therapeutics with a rating of Outperform and set a new price target of $8.00
• 729d
  William Blair initiated coverage on CAMP4 Therapeutics

  William Blair initiated coverage of CAMP4 Therapeutics with a rating of Outperform
• 729d
  Piper Sandler initiated coverage on CAMP4 Therapeutics with a new price target

  Piper Sandler initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $18.00
• 729d
  JP Morgan initiated coverage on CAMP4 Therapeutics with a new price target

  JP Morgan initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $23.00

Other CAMP categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 4
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings